Fake drugs problem on the rise

An estimated 10% of medical products circulating in low- and middle-income countries is either substandard or falsified, according to new research from WHO, outlined in a recently published report: WHO Global Surveillance and Monitoring System for substandard and falsified medical products.

This means that people are taking medicines that fail to treat or prevent disease. Not only is this a waste of money for individuals and health systems that purchase these products, but substandard or falsified medical products can cause serious illness or even death.

The report notes that “although it is extremely difficult to quantify the problem precisely, recent efforts by the World Health Organization (WHO) and others to support countries in tracking and reporting substandard and falsified medical productssuggest the problem is on the rise”.

“Substandard and falsified medicines particularly affect the most vulnerable communities,” says Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Imagine a mother who gives up food or other basic needs to pay for her child’s treatment, unaware that the medicines are substandard or falsified, and then that treatment causes her child to die. This is unacceptable. Countries have agreed on measures at the global level – it is time to translate them into tangible action.”

Established in 2013, WHO’s Global Surveillance and Monitoring System for substandard and falsified medical products (GSMS) is still in its infancy. Prior to 2013, there was no global reporting of this information, however in the past four years WHO has received 1500 reports of cases of substandard or falsified products. It is clear that these cases represent only a fraction of the problem.

Of these, antimalarials and antibiotics are the most commonly reported. Most of the reports (42%) come from the WHO African Region, 21% from the WHO Region of the Americas, and 21% from the WHO European Region.

This is likely just a small fraction of the total problem and many cases may be going unreported. For example, only 8% of reports of substandard or falsified products to WHO came from the WHO Western Pacific Region, 6% from the WHO Eastern Mediterranean Region, and just 2% from the WHO South-East Asia Region.

According to the report the numerical distribution of cases is influenced by the roll-out of the GSMS system, which includes training for staff appointed by national medicine regulators to act as focal points interactingwith the global reporting system. As of July 2017, staff from 126 WHO Member States had been trained in 17 workshops. There is a striking association between increased training and increases in cases reported, suggesting that the greater the effort made to look for substandard and falsified medical products, the more of them will be found.

“Many of these products, like antibiotics, are vital for people’s survival and wellbeing,” says Dr Mariângela Simão, Assistant Director-General for Access to Medicines, Vaccines and Pharmaceuticals at WHO. “Substandard or falsified medicines not only have a tragic impact on individual patients and their families, but also are a threat to antimicrobial resistance, adding to the worrying trend of medicines losing their power to treat”.

WHO has received reports of substandard or falsified medical products ranging from cancer treatment to contraception. They are not confined to high-value medicines or well-known brand names and are split almost evenly between generic and patented products.

Treatment failure
In conjunction with the first report from the Global Surveillance and Monitoring System, WHO is publishing research that estimates a 10.5% failure rate in all medical products used in low- and middle-income countries.

This study was based on more than 100 published research papers on medicine quality surveys done in 88 low- and middleincome countries involving 48,000 samples of medicines. Lack of accurate data means that these estimates are just an indication of the scale of the problem. More research is needed to more accurately estimate the threat posed by substandard and falsified medical products.

Based on 10% estimates of substandard and falsified medicines, a modelling exercise developed by the University of Edinburgh estimates that 72,000 to 169,000 children may be dying each year from pneumonia due to substandard and falsified antibiotics. A second model done by the London School of Hygiene and Tropical Medicine estimates that 116,000 (64,000 – 158,000) additional deaths from malaria could be caused every year by substandard and falsified antimalarials in sub-Saharan Africa, with a cost of US$38.5 million (21.4 million – 52.4 million) to patients and health providers for further care due to failure of treatment.

Good governance
Substandard medical products reach patients when the tools and technical capacity to enforce quality standards in manufacturing, supply and distribution are limited. Falsified products, on the other hand, tend to circulate where inadequate regulation and governance are compounded by unethical practice by wholesalers, distributors, retailers and health care workers. A high proportion of cases reported to WHO occur in countries with constrained access to medical products.

Modern purchasing models such as online pharmacies can easily circumvent regulatory oversight. These are especially popular in high-income countries, but more research is needed to determine the proportion and impact of sales of substandard or falsified medical products.

Globalization is making it harder to regulate medical products. Many falsifiers manufacture and print packaging in different countries, shipping components to a final destination where they are assembled and distributed. Sometimes, offshore companies and bank accounts have been used to facilitate the sale of falsified medicines.

“The bottom line is that this is a global problem,” says Dr Simão. “Countries need to assess the extent of the problem at home and cooperate regionally and globally to prevent the traffic of these products and improve detection and response.”

Tackling the problem
The Executive Summary of the report outlines how the problem can be tackled and notes that three interconnected approaches are required.

I. The first focuses on preventing the sale and consumption of substandard and falsified medical products;

II. the second on implementing systems to detect any substandard or falsified products that are already in the supply chain; and

III. the third requires authorities to respond quickly and proportionately to any incidents that are detected.

WHO medical products alert



Date of upload: 22nd Jan 2018

                                               Copyright © 2018 All Rights Reserved.